# **ECS Botanics Holdings Ltd (ASX:ECS)**



### **ASX Announcement**

### 13 November 2023

## Launch of THC and CBD pastilles and vapes

- ECS to launch innovative white-label THC and CBD pastilles and THC vape products
- Significantly increases the ECS Botanics white-label product range
- Range additions provide alternative delivery methods for the Australian medicinal cannabis market
- Complements existing B2B range, leveraging ECS' cultivation and pharmaceutical grade production facilities and manufacturing expertise
- Updated Managing Director's Remuneration

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), is pleased to advise that it is launching a range of GMP-certified cannabidiol (CBD) and tetrahydrocannabinol (THC) pastilles and THC vapes.

The pastilles are available in both CBD and THC forms, as well as combinations of both. The whitelabel range is sugar-free, plant-based, and is offered in a range of flavours and colours. Pastilles are chewed and dissolved in the mouth, enabling the active ingredients to rapidly enter the bloodstream.





ECS is also launching a white-label THC distillate vape infused with additional terpenes. Australian Made, the vape cartridges use oil concentrates derived from ECS' pharmaceutical-grade extracts derived from the Company's Australian-grown flower, packaged in child-resistant packaging. The cartridges will be available in 0.5 and 1-mL. This new THC distillate vape infused with additional terpenes replaces the previous dried flower vaporiser cartridge product that ECS was looking to introduce to the market in 2023.



Products are expected to be in the market before the end of this quarter and will increase the ECS Botanics white-label offering to a range of four products -flowers, oils, pastilles and vapes.

## ECS Managing Director, Nan-Maree Schoerie commented:

"The expansion of our B2B product range to include GMP-certified CBD and THC pastilles and THC vapes provides our customers and their patients with alternative dosage methods. These products are manufactured under stringent pharmaceutical-grade GMP standards that meet all TGA quality and compliance requirements to manufacture pharmaceutical-grade cannabinoid products.

"Pastilles and vapes are relatively new delivery methods in the Australian market and will provide local patients with advanced treatment options. These innovative product ranges complement our existing B2B offering, leveraging our expertise to meet growing consumer demand for premium medicinal cannabis solutions. We have already received pre-orders for these new products and expect demand to increase rapidly."

The Company further advises that - effective immediately - and following the Company's significantly improved performance in financial year 2023, the base remuneration of managing director Nan-Maree Schoerie has been adjusted to \$315,500 exclusive of superannuation.

-ENDS-

#### **About ECS Botanics Holdings Ltd**

ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.

For further information, please contact: info@ecs-botanics.com